{"id":3984,"date":"2017-08-13T07:38:59","date_gmt":"2017-08-13T07:38:59","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/andromedic-esho-2014\/"},"modified":"2026-02-17T09:55:49","modified_gmt":"2026-02-17T09:55:49","slug":"andromedic-esho-2014","status":"publish","type":"page","link":"https:\/\/andromedichyperthermia.com\/et\/andromedic-esho-2014\/","title":{"rendered":"Andromedic sekkumine ESHO 2014"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/et\/andromedic-esho-2014\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/et\/andromedic-esho-2014\/\",\n      \"name\": \"Kliinilised uuringud Andromedic HyDeep 600 WM s\u00fcsteemiga - ESHO kongress\",\n      \"description\": \"Andmed HyDeep 600 WM kliiniliste uuringute kohta emakakaelav\u00e4hi ravis ja multitsentrilised teostatavusuuringud, mida esitleti ESHO kongressil.\",\n      \"inLanguage\": \"et-EE\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"mainEntity\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n      \"about\": [\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"LACC emakakaelav\u00e4hi uuring\",\n          \"description\": \"8 patsiendiga l\u00e4bi viidud uuring, mis n\u00e4itab 100% lokaalset kontrolli, kasutades HyDeep 600 WM s\u00fcsteemi ja HDR-brahh\u00fcteraapiat.\",\n          \"studySubject\": { \"@type\": \"MedicalCondition\", \"name\": \"Emakakaelav\u00e4hk\" }\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"Hispaania juhtkontrolluuring\",\n          \"description\": \"Laiaulatuslik teostatavusuuring 293 patsiendiga, mis h\u00f5lmas 9 erinevat kasvaja asukohta.\",\n          \"sampleSize\": 293,\n          \"studyStatus\": \"Published\"\n        }\n      ],\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" }\n      ]\n    },\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"HyDeep 600WM\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"T\u00e4iustatud onkoloogiline h\u00fcpertermia s\u00fcsteem \/ professionaalne moduleeritud RF-h\u00fcpertermia seade (13,56 MHz) lokaalseks s\u00fcvah\u00fcpertermiaks.\",\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/et\/contact\/\",\n        \"priceSpecification\": {\n          \"@type\": \"PriceSpecification\",\n          \"description\": \"Hind soovi korral\"\n        }\n      },\n      \"review\": {\n        \"@type\": \"Review\",\n        \"author\": { \"@type\": \"Person\", \"name\": \"Dr. med. Veronica Iatan\" },\n        \"reviewRating\": { \"@type\": \"Rating\", \"ratingValue\": \"5\", \"bestRating\": \"5\" },\n        \"reviewBody\": \"Juhtiv s\u00fcvah\u00fcpertermia tehnoloogia koos kliiniliselt valideeritud protokollidega.\"\n      }\n    },\n    {\n      \"@type\": \"MedicalOrganization\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\",\n      \"name\": \"Andromedic Srl\"\n    }\n  ]\n}\n<\/script><\/p>\n<div style=\"line-height: 1.6; color: #333; max-width: 1100px; margin: auto; font-family: 'Segoe UI', Helvetica, sans-serif; background-color: #fff; padding: 20px;\">\n<header style=\"border-bottom: 4px solid #1a2a6c; padding-bottom: 25px; margin-bottom: 40px; text-align: center;\">\n<h1 style=\"color: #1a2a6c; font-size: 28px; font-weight: 800; text-transform: uppercase; margin-bottom: 10px;\">Euroopa H\u00fcpertermilise Onkoloogia Selts: ESHO 2014<\/h1>\n<h2 style=\"color: #b21f1f; font-size: 20px; font-weight: 600;\">Andromedicu sekkumine \u2013 Dr Salvatore Conte<\/h2>\n<p style=\"font-size: 16px; max-width: 850px; margin: 15px auto; color: #555;\"><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\">ESHO 2014<\/a> konverentsil teatas <a href=\"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\"><strong>Dr Salvatore Conte<\/strong><\/a> Andromedicu h\u00fcpertermia meeskonna olulisest teet\u00e4hisest: vaid 18 kuuga on edukalt toodetud ja tarnitud 25 <a href=\"https:\/\/andromedichyperthermia.com\/et\/sugav-lokaalne-hupertermia-seade\/\"><strong>HyDeep 600 WM<\/strong> lokaalse s\u00fcvah\u00fcpertermia seadet<\/a> ning t\u00e4iendavad 40 \u00fcksust on suunatud India turule.<\/p>\n<\/header>\n<div style=\"margin-bottom: 50px; border-radius: 15px; overflow: hidden; box-shadow: 0 10px 25px rgba(0,0,0,0.2);\">\n<p><iframe loading=\"lazy\" title=\"intervento Andromedic   Esho 20014\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/fgMdXxoJ1cI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<\/div>\n<h2 style=\"text-align: center; color: #1a2a6c; margin-bottom: 30px; text-transform: uppercase;\">Esitletud kliinilised uuringud: HyDeep 600 WM arenenud onkoloogiline h\u00fcpertermia<\/h2>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #1a2a6c; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">1. Kemoradioteraapia + h\u00fcpertermia + HDR brahhiteraapia LACC ravis<\/h3>\n<\/div>\n<div style=\"padding: 30px; background: #f9f9f9;\">\n<p><strong>EESM\u00c4RGID:<\/strong> Uurida igan\u00e4dalase tsisplatiini ja lokaalse s\u00fcvah\u00fcpertermia kombineerimise tulemusi koos IMRT ja sellele j\u00e4rgneva brahhiteraapiaga (BRT) lokaalselt arenenud emakakaelav\u00e4hi (LACC) korral.<\/p>\n<div style=\"background: #fff; padding: 20px; border-radius: 10px; margin: 20px 0; border-left: 5px solid #b21f1f;\">\n<p><strong>MATERJALID JA MEETODID:<\/strong><\/p>\n<ul style=\"margin-top: 10px; font-size: 15px;\">\n<li><strong>Patsientide r\u00fchm:<\/strong> 8 patsienti (3 IIB staadium, 1 IIIB, 2 NEI, 3 LRCC).<\/li>\n<li><strong>Protokoll:<\/strong> 50,4 Gy vaagna l\u00fcmfis\u00f5lmedele koos SIB-ga GTV-le (kokku 61,8 Gy) 28 fraktsioonis. BRT doos: 21 Gy 3 fraktsioonis.<\/li>\n<li><strong>Kaasnev ravi:<\/strong> Igan\u00e4dalane tsisplatiin 40mg\/m\u00b2 + HT \u00fcks kord n\u00e4dalas.<\/li>\n<\/ul>\n<\/div>\n<div style=\"background: #e8f5e9; padding: 20px; border-radius: 10px; border: 1px solid #2e7d32;\">\n<p><strong style=\"color: #1b5e20; font-size: 17px; display: block; margin-bottom: 10px;\">TULEMUSED JA J\u00c4RELDUSED:<\/strong><\/p>\n<p style=\"font-size: 16px; font-weight: bold; margin: 0;\">SAAVUTATI 100% LOKAALNE KONTROLL. Raviga seotud \u00e4gedat ega hilist 3.\u20134. astme toksilisust ei t\u00e4heldatud.<\/p>\n<p style=\"margin-top: 10px; font-style: italic;\">&#8220;Lokaalse s\u00fcvah\u00fcpertermia lisamine kemoradioteraapiale on perspektiivikas uus strateegia, mida patsiendid taluvad suurep\u00e4raselt.&#8221;<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #b21f1f; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">2. Kvaasi-teostatavusuuring (juhtkontrolluuring) \u2013 lokaalne s\u00fcvah\u00fcpertermia \u2013 Andaluusia, Hispaania<\/h3>\n<\/div>\n<div style=\"padding: 30px;\">\n<p><strong>Sissejuhatus:<\/strong> Esimene kliiniline uuring Hispaanias, mis kombineerib lokaalset s\u00fcvah\u00fcpertermiat standardsete v\u00e4hiravimeetoditega riiklikus tervishoius\u00fcsteemis.<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 25px 0;\">\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Uuringu disain:<\/strong> Prospektiivne juhtkontrolluuring. Kokku 293 patsienti (97 aktiivses faasis vs 196 kontrollr\u00fchmas). 9 kasvaja lokalisatsiooni.<\/div>\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Ravi parameetrid:<\/strong> 10 seanssi (2\u20133 korda n\u00e4dalas), kestusega 1 tund, v\u00f5imsus 150W\u2013400W, kasutades <strong>HyDeep 600WM moduleeritud h\u00fcpertermia seadet<\/strong>.<\/div>\n<\/div>\n<h4 style=\"color: #1a2a6c; border-bottom: 2px solid #b21f1f; display: inline-block; padding-bottom: 5px;\">Esialgsed andmed (22 patsiendi alar\u00fchm):<\/h4>\n<ul style=\"margin-top: 15px; font-size: 14px; column-count: 2;\">\n<li><strong>Glioblastoom (2j)<\/strong><\/li>\n<li><strong>Pea ja kael (7j)<\/strong><\/li>\n<li><strong>Operatsioonieelne p\u00e4rasool (3j)<\/strong><\/li>\n<li><strong>Rinnav\u00e4hk (3j)<\/strong><\/li>\n<li><strong>Kops (NSCLC &#8211; 11j)<\/strong><\/li>\n<li><strong>Eesn\u00e4\u00e4re (4j)<\/strong><\/li>\n<li><strong>Emakakael ja metastaasid<\/strong><\/li>\n<\/ul>\n<div style=\"display: flex; flex-wrap: wrap; gap: 15px; margin: 25px 0;\">\n<div style=\"flex: 1; min-width: 200px; background: #fffde7; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #fbc02d;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">81.2%<\/span><br \/>\n<strong>K\u00d5RGE TALUVUS<\/strong><br \/>\n<small>Patsiendid rahul v\u00f5i v\u00e4ga rahul<\/small><\/div>\n<div style=\"flex: 1; min-width: 200px; background: #f1f8e9; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #7cb342;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">66.6%<\/span><br \/>\n<strong>TOKSILISUS PUUDUB<\/strong><br \/>\n<small>K\u00f5rvaltoimeid ei esinenud<\/small><\/div>\n<\/div>\n<p style=\"background: #f4f7f9; padding: 15px; border-radius: 8px; border-left: 4px solid #1a2a6c;\"><strong>J\u00c4RELDUS:<\/strong> Lokaalne s\u00fcvah\u00fcpertermia on teostatav rutiinses riiklikus haiglaravis ilma t\u00e4iendavate erakorraliste ressurssideta. \u00d5ige patsiendivalik tagab minimaalse (1. astme) toksilisuse.<\/p>\n<div style=\"text-align: center; margin-top: 30px;\"><a style=\"display: inline-block; background: #b21f1f; color: #fff; padding: 14px 30px; text-decoration: none; border-radius: 5px; font-weight: 800; text-transform: uppercase; box-shadow: 0 4px 10px rgba(178,31,31,0.3);\" href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Protocolo-del-ensayo-MAG-HIP-2013-01-11-EN.pdf\">Laadi alla uuringu t\u00e4ielik protokoll (PDF)<\/a><\/div>\n<\/div>\n<\/section>\n<div style=\"margin-top: 40px;\">\n<h3 style=\"text-align: center; color: #1a2a6c; text-transform: uppercase; letter-spacing: 1px;\">ESHO teaduslikud posterid ja dokumentatsioon<\/h3>\n<div id='gallery-1' class='gallery galleryid-3984 gallery-columns-1 gallery-size-full'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/et\/kliinilised-uuringud\/preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"590\" height=\"837\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1328\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg 590w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-211x300.jpg 211w\" sizes=\"auto, (max-width: 590px) 100vw, 590px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1328'>\n\t\t\t\tPreliminary results of chemoradiation plus Andromedic hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/et\/kliinilised-uuringud\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-b-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"569\" height=\"831\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1307\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg 569w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B-205x300.jpg 205w\" sizes=\"auto, (max-width: 569px) 100vw, 569px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1307'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/et\/kliinilised-uuringud\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"568\" height=\"826\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1286\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1286'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia HyDeep 600WM treatment with standard cancer treatments and describing patterns of response\n\t\t\t\t<\/figcaption><\/figure>\n\t\t<\/div>\n\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Euroopa H\u00fcpertermilise Onkoloogia Selts: ESHO 2014 Andromedicu sekkumine \u2013 Dr Salvatore Conte ESHO 2014 konverentsil teatas Dr Salvatore Conte Andromedicu h\u00fcpertermia meeskonna olulisest teet\u00e4hisest: vaid 18 kuuga on edukalt toodetud ja tarnitud 25 HyDeep 600 WM lokaalse s\u00fcvah\u00fcpertermia seadet ning t\u00e4iendavad 40 \u00fcksust on suunatud India turule. Esitletud kliinilised uuringud: HyDeep 600 WM arenenud onkoloogiline&hellip;<\/p>\n","protected":false},"author":1,"featured_media":17340,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-gutentor-full-width.php","meta":{"footnotes":""},"class_list":["post-3984","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/pages\/3984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/comments?post=3984"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/pages\/3984\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media\/17340"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media?parent=3984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}